Insider Selling: Simulations Plus, Inc. (NASDAQ:SLP) Director Sells 20,000 Shares of Stock

Simulations Plus, Inc. (NASDAQ:SLP) Director Walter S. Woltosz sold 20,000 shares of the firm’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $31.76, for a total transaction of $635,200.00. Following the completion of the transaction, the director now directly owns 3,442,584 shares of the company’s stock, valued at approximately $109,336,467.84. This represents a 0.58 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Simulations Plus Trading Down 1.4 %

Shares of Simulations Plus stock traded down $0.44 on Tuesday, hitting $31.33. The stock had a trading volume of 200,419 shares, compared to its average volume of 138,342. The stock has a market cap of $628.79 million, a price-to-earnings ratio of 63.47 and a beta of 0.76. The company’s 50 day moving average price is $30.83 and its 200 day moving average price is $37.44. Simulations Plus, Inc. has a 52-week low of $27.07 and a 52-week high of $51.22.

Simulations Plus (NASDAQ:SLP) last posted its quarterly earnings data on Wednesday, October 23rd. The technology company reported $0.06 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.02. The firm had revenue of $18.70 million during the quarter, compared to analysts’ expectations of $19.73 million. Simulations Plus had a return on equity of 6.16% and a net margin of 14.15%. The firm’s quarterly revenue was up 19.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.18 EPS. Analysts predict that Simulations Plus, Inc. will post 1.12 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its position in shares of Simulations Plus by 1.1% in the first quarter. Vanguard Group Inc. now owns 1,135,105 shares of the technology company’s stock valued at $46,710,000 after purchasing an additional 12,636 shares during the period. Price T Rowe Associates Inc. MD increased its stake in shares of Simulations Plus by 5.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,048 shares of the technology company’s stock valued at $414,000 after acquiring an additional 562 shares during the last quarter. Public Employees Retirement System of Ohio purchased a new position in shares of Simulations Plus during the 1st quarter worth about $1,082,000. SG Americas Securities LLC acquired a new stake in shares of Simulations Plus in the second quarter worth approximately $1,320,000. Finally, InTrack Investment Management Inc grew its holdings in Simulations Plus by 1.1% in the second quarter. InTrack Investment Management Inc now owns 31,665 shares of the technology company’s stock valued at $1,540,000 after purchasing an additional 330 shares during the period. 78.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. BTIG Research reduced their price target on Simulations Plus from $60.00 to $50.00 and set a “buy” rating for the company in a research report on Thursday, October 24th. Stephens began coverage on shares of Simulations Plus in a report on Friday, November 15th. They issued an “overweight” rating and a $39.00 price objective on the stock. William Blair reiterated an “outperform” rating on shares of Simulations Plus in a report on Wednesday, November 6th. Finally, StockNews.com downgraded shares of Simulations Plus from a “hold” rating to a “sell” rating in a research note on Monday, November 4th. One analyst has rated the stock with a sell rating, one has given a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Simulations Plus presently has a consensus rating of “Moderate Buy” and an average price target of $51.40.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.